Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Ruiz-Patiño

P2.13-11 EGFR Amplification and Sensitizing Mutations Correlates With Survival From Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)

Journal of Thoracic Oncology

English

P3.01-11 Depression and Inflammation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Related publications

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Clinical Cancer Research

Cancer Research

Oncology

2011

English

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

Experimental and Therapeutic Medicine

English

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

Journal of Thoracic Oncology

English

P2.13-36 Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients With Oncogenic Driver Mutations in China

Journal of Thoracic Oncology

English

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

English

HER2/neu (ERBB2) Expression and Gene Amplification Correlates With Better Survival in Esophageal Adenocarcinoma

English

Correlation Between Serum CEA Levels and EGFR Mutations in Chinese Nonsmokers With Lung Adenocarcinoma

Acta Pharmacologica Sinica

Medicine

Pharmacology

2014

English

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma

PLoS ONE

Multidisciplinary

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Ruiz-Patiño

P2.13-11 EGFR Amplification and Sensitizing Mutations Correlates With Survival From Erlotinib in Lung Adenocarcinoma Patients (MutP-CLICAP¶)

P3.01-11 Depression and Inflammation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

Related publications

Erlotinib in Symptomatic Brain Metastases From a Lung Adenocarcinoma With a Sensitizing EGFR Mutation

EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma

Erlotinib Has Better Efficacy Than Gefitinib in Adenocarcinoma Patients Without EGFR-activating Mutations, but Similar Efficacy in Patients With EGFR-activating Mutations

P2.13-22 Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients With Both T790M and Sensitizing EGFR Mutation

P2.13-36 Analysis of CDK4/6 Pathway Activity in Lung Adenocarcinoma Patients With Oncogenic Driver Mutations in China

Presence of the Minor EGFR T790M Mutation Is Associated With Drug-Sensitive EGFR Mutations in Lung Adenocarcinoma Patients

HER2/neu (ERBB2) Expression and Gene Amplification Correlates With Better Survival in Esophageal Adenocarcinoma

Correlation Between Serum CEA Levels and EGFR Mutations in Chinese Nonsmokers With Lung Adenocarcinoma

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK Among Treatment-Naïve Patients With Advanced Lung Adenocarcinoma